✦ LIBER ✦

Tolterodine, a New Antimuscarinic Drug for Treatment of Bladder Overactivity — A Comment

✍ Scribed by David D. Short

Book ID: 115047619
Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 13 KB
Volume: 19
Category: Article
ISSN: 0277-0008
DOI: 10.1592/phco.19.15.1188.30579

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tolterodine, a New Antimuscarinic Drug f

Tolterodine, a New Antimuscarinic Drug for Treatment of Bladder Overactivity

✍ David R. P. Guay 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Urodynamic and other effects of tolterod

Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity

✍ M. M. S. Stahl; B. Ekström; B. Sparf; A. Mattiasson; K.-E. Andersson 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

Pharmacokinetics and toxicity of antimus

Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females

✍ Leone Roberti Maggiore, Umberto; Salvatore, Stefano; Alessandri, Franco; Remorgi 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 705 KB

Solifenacin: a new drug for the treatmen

Solifenacin: a new drug for the treatment of overactive bladder and detrusor overactivity

✍ Wyndaele, Jean-Jacques 📂 Article 📅 2006 🏛 Future Medicine 🌐 English ⚖ 268 KB

Tolterodine, a New Antimuscarinic Agent:

Tolterodine, a New Antimuscarinic Agent: As Effective but Better Tolerated Than Oxybutynin in Patients With an Overactive Bladder

✍ Abrams, P.; Freeman, R.; Anderstrom, C.; Mattiasson, A. 📂 Article 📅 1999 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 232 KB

Cost-effectiveness of new treatments for

Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model

✍ Gisela Kobelt; Linus Jönsson; Anders Mattiasson 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

Economic analyses of interventions for chronic diseases require evaluations over a long timeframe to illustrate the benefits and costs of treatments. Clinical trials are generally short and carried out in strictly controlled conditions. They are therefore of limited value for economic evaluation aim